Stay updated on Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page.

Latest updates to the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page
- CheckyesterdayChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded the Lancet Oncology publication citation for SERENA-2 and removed the associated Erratum reference.SummaryDifference0.0%

- Check30 days agoChange DetectedNaples, Italy, 80131 was added as a study location and Napoli, Italy, 80131 was replaced with the English name Naples. The page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check44 days agoChange DetectedPublication entry for SERENA-2 (Lancet Oncol. 2024) and its erratum added; the entry revision updated from v3.4.2 to v3.4.3 to reflect this change.SummaryDifference0.1%

- Check66 days agoChange Detected- Page revision updated from v3.4.1 to v3.4.2. No substantive changes to core study details were observed.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page shows a revision update from v3.4.0 to v3.4.1, with no visible changes to study information.SummaryDifference0.0%

Stay in the know with updates to Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page.